{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:59:00Z","timestamp":1790279940735,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-026-02408-x","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T07:27:26Z","timestamp":1788938846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond the Liver: Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Associated 35% Higher Risk of Clinically Diagnosed Heart Failure With Preserved Ejection Fraction (HFpEF)"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-2868","authenticated-orcid":false,"given":"Mona A.","family":"Hegazy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3538-4441","authenticated-orcid":false,"given":"Saeed","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5461-7861","authenticated-orcid":false,"given":"Marwa Mostafa","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6558-392X","authenticated-orcid":false,"given":"Abeer","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5517-1083","authenticated-orcid":false,"given":"Syrine","family":"Bellakhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-3147","authenticated-orcid":false,"given":"Nadia Mostafa","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5589-1037","authenticated-orcid":false,"given":"Amin R.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"1","key":"2408_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1055\/s-0044-1785196","volume":"44","author":"CM Canivet","year":"2024","unstructured":"Canivet CM, Boursier J, Loomba R. New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice. Semin Liver Dis. 2024;44(1):35\u201342. https:\/\/doi.org\/10.1055\/s-0044-1785196.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"2408_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology"},{"key":"2408_CR3","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. (2022) May 03;79(17): e263-e421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012","DOI":"10.1016\/j.jacc.2021.12.012"},{"issue":"27","key":"2408_CR4","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129\u2013200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128.","journal-title":"Eur Heart J"},{"key":"2408_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ehf2.12222","volume":"5","author":"Y Akiomi Yoshihisa","year":"2018","unstructured":"Akiomi Yoshihisa Y, Sato T, Yokokawa T, Sato S, Suzuki M, Oikawa A, Kobayashi T, Yamaki H, Kunii. Kazuhiko Nakazato, Shu-ichi Saitoh and Yasuchika Takeishi. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail. 2018;5:262\u201370. https:\/\/doi.org\/10.1002\/ehf2.12222.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"2408_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589\u2013600. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.013.","journal-title":"J Hepatol"},{"key":"2408_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327672","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, Tilg H, Byrne C, Targher G. Non-Alcoholic Fatty Liver Disease and Risk of New-Onset Heart Failure: An Updated Meta-Analysis of About 11 million Individuals. Gut. 2022. https:\/\/doi.org\/10.1136\/gutjnl-2022-327672.","journal-title":"Gut"},{"key":"2408_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s12020-019-02070-0","volume":"66","author":"M Borges-Canha","year":"2019","unstructured":"Borges-Canha M, Neves Lib\u00e2nioD, Von-Hafe M, Vale C, Ara\u00fajo-Martins M, Leite A, Pimentel-Nunes P, Carvalho D. Leite-Moreira A.Association between nonalcoholic fatty liver disease and cardiac function and structure\u2014a meta-analysis. Endocrine. 2019;66:467\u201376. https:\/\/doi.org\/10.1007\/s12020-019-02070-0.","journal-title":"Endocrine"},{"key":"2408_CR9","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.dld.2018.09.004","volume":"50","author":"K Wijarnpreecha","year":"2018","unstructured":"Wijarnpreecha K, Lou S, Panjawatanan P, Cheungpasitporn W, Pungpapong S, Lukens F, Ungprasert P. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis. Dig Liver Disease. 2018;50:1166\u201375. https:\/\/doi.org\/10.1016\/j.dld.2018.09.004.","journal-title":"Dig Liver Disease"},{"key":"2408_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jclinepi.2022.04.006","volume":"150","author":"E Aromataris","year":"2022","unstructured":"Aromataris E, Stern C, Lockwood C, Barker TH, Klugar M, Jadotte Y, Evans C, Ross-White A, Lizarondo L, Stephenson M, McArthur A. JBI series paper 2: tailored evidence synthesis approaches are required to answer diverse questions: a pragmatic evidence synthesis toolkit from JBI. J Clin Epidemiol. 2022;150:196\u2013202. https:\/\/doi.org\/10.1016\/j.jclinepi.2022.04.006.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2408_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of\u2010bias Visualization (robvis): an R package and Shiny web app for visualizing risk\u2010of\u2010bias assessments. Res synthesis methods. 2021;12(1):55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res synthesis methods"},{"key":"2408_CR12","doi-asserted-by":"publisher","first-page":"e021654","DOI":"10.1161\/jaha.121.021654","volume":"10","author":"M Fudim","year":"2021","unstructured":"Fudim M, Zhong L, Patel KV, Khera R, Abdelmalek MF, Diehl AM, et al. Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries. J Am Heart Assoc. 2021;10:e021654. https:\/\/doi.org\/10.1161\/jaha.121.021654.","journal-title":"J Am Heart Assoc"},{"key":"2408_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1183075","author":"W Jiang","year":"2023","unstructured":"Jiang W, Liu Z, Liu S, Du T. Associations of advanced liver fibrosis with heart failure with preserved ejection fraction in type 2 diabetic patients according to obesity and metabolic goal achievement status. Front Endocrinol. 2023. https:\/\/doi.org\/10.3389\/fendo.2023.1183075.","journal-title":"Front Endocrinol"},{"key":"2408_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3567","author":"KC Chang","year":"2025","unstructured":"Chang KC, Su TH, Wu CK, Huang SC, Tseng TC, Hong CM, Hsu SJ, Liu CH, Hung- Yang HC, Liu CJ, Kao JH. Metabolic dysfunction-associated steatotic liver disease is associated with increased risks of heart failure. Eur J Heart Fail. 2025. https:\/\/doi.org\/10.1002\/ejhf.3567.","journal-title":"Eur J Heart Fail"},{"key":"2408_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20406223221119626","volume":"13","author":"W Li","year":"2022","unstructured":"Li W, Wen W, Xie D, Qiu M, Cai X, Zheng S, Huang Y. Association between non-alcoholic fatty liver disease and risk of incident heart failure: a meta-analysis of observational studies. Ther Adv Chronic Dis. 2022;13:1\u201311. https:\/\/doi.org\/10.1177\/20406223221119626.","journal-title":"Ther Adv Chronic Dis"},{"key":"2408_CR16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/gutjnl-2022-327672","volume":"72","author":"A Mantovani","year":"2023","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, Tilg H, Byme CD. Targher G.Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2023;72:372\u201380. https:\/\/doi.org\/10.1136\/gutjnl-2022-327672.","journal-title":"Gut"},{"key":"2408_CR17","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1002\/ejhf.2333","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726. https:\/\/doi.org\/10.1002\/ejhf.2333.","journal-title":"Eur Heart J"},{"key":"2408_CR18","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70:2476\u201386. https:\/\/doi.org\/10.1016\/j.jacc.2017.08.074.","journal-title":"J Am Coll Cardiol"},{"key":"2408_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.31083\/j.rcm.2020.04.154","volume":"21","author":"N Nair","year":"2020","unstructured":"Nair N. Epidemiology and pathogenesis of heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020;21:531\u201340. https:\/\/doi.org\/10.31083\/j.rcm.2020.04.154.","journal-title":"Rev Cardiovasc Med"},{"key":"2408_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","volume":"329","author":"MM Redfield","year":"2023","unstructured":"Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023;329:827\u201338. https:\/\/doi.org\/10.1001\/jama.2023.2020.","journal-title":"JAMA"},{"key":"2408_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/s0140-6736(23)02756-3","volume":"403","author":"P Campbell","year":"2024","unstructured":"Campbell P, Rutten FH, Lee MM, Hawkins NM, Petrie MC. Heart failure with preserved ejection fraction: everything the clinician needs to know. Lancet. 2024;403:1083\u201392. https:\/\/doi.org\/10.1016\/s0140-6736(23)02756-3.","journal-title":"Lancet"},{"key":"2408_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1161\/circheartfailure.110.959890","volume":"4","author":"M Haass","year":"2011","unstructured":"Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: resultsfrom the Irbesartan in Heart Failure with Preserved EjectionFraction (I-PRESERVE) trial. Circ Heart Fail. 2011;4:324\u201331. https:\/\/doi.org\/10.1161\/circheartfailure.110.959890.","journal-title":"Circ Heart Fail"},{"key":"2408_CR23","doi-asserted-by":"publisher","first-page":"e003116","DOI":"10.1161\/circheartfailure.115.003116","volume":"9","author":"JE Ho","year":"2016","unstructured":"Ho JE, Enserro D, Brouwers FP, Kizer JR, Shah SJ, Psaty BM, et al. Predicting heart failure with preserved and reduced ejection fraction: the International Collaboration on Heart Failure Sub-types. Circ Heart Fail. 2016;9:e003116. https:\/\/doi.org\/10.1161\/circheartfailure.115.003116.","journal-title":"Circ Heart Fail"},{"key":"2408_CR24","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacc.2016.11.081","volume":"69","author":"A Pandey","year":"2017","unstructured":"Pandey A, LaMonte M, Klein L, Ayers C, Psaty BM, Eaton CB, et al. Relationship between physical activity, body mass index, and risk of heart failure. J Am Coll Cardiol. 2017;69:1129\u201342. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.081.","journal-title":"J Am Coll Cardiol"},{"key":"2408_CR25","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/s2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361. https:\/\/doi.org\/10.1016\/s2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10319","key":"2408_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/s0140-6736(21)01701-3","volume":"399","author":"TH Karlsen","year":"2022","unstructured":"Karlsen TH, Sheron N, Zelber-Sagi S, et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2022;399(10319):61\u2013116. https:\/\/doi.org\/10.1016\/s0140-6736(21)01701-3.","journal-title":"Lancet"},{"key":"2408_CR27","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/jci23621","volume":"115","author":"KL Donnelly","year":"2005","unstructured":"Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343\u201351. https:\/\/doi.org\/10.1172\/jci23621.","journal-title":"J Clin Invest"},{"key":"2408_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22:63. https:\/\/doi.org\/10.1186\/s12902-022-00980-1.","journal-title":"BMC Endocr Disord"},{"key":"2408_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.36011\/cpp.2022.4.e17","volume":"4","author":"DJ Koo","year":"2022","unstructured":"Koo DJ, Lee WY. The crosstalk between insulin resistance andnonalcoholic fatty liver disease\/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence? Cardiovasc Prev Pharmacother. 2022;4:132\u201341. https:\/\/doi.org\/10.36011\/cpp.2022.4.e17.","journal-title":"Cardiovasc Prev Pharmacother"},{"key":"2408_CR30","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","volume":"73","author":"EP Stahl","year":"2019","unstructured":"Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic fatty liver disease and the heart:JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:948\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.050.","journal-title":"J Am Coll Cardiol"},{"key":"2408_CR31","doi-asserted-by":"publisher","unstructured":"Coombes JD, Choi SS, Swiderska-Syn M, Manka P, Reid DT, Palma E, Briones-Orta MA, Xie G, Younis R, Kitamura N, Della Peruta M, Bitencourt S, Doll\u00e9 L, OoYH, Mi Z, Kuo PC, Williams R, Chokshi S, Canbay A, Claridge LC, Eksteen B, Diehl AM, Syn WK. Osteopontin is a proximal effector of leptin- mediated non-alcoholic steatohepatitis (NASH) brosis. Biochim Biophys Acta1862. 2016;135\u201344. https:\/\/doi.org\/10.1016\/j.bbadis.2015.10.028.","DOI":"10.1016\/j.bbadis.2015.10.028"},{"key":"2408_CR32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.hfc.2014.04.008","volume":"10","author":"SJ Shah","year":"2014","unstructured":"Shah SJ, Katz DH, Deo RC. Phenotypic spectrum of heart failure with preserved ejection fraction. Heart Fail Clin. 2014;10:407\u201318. https:\/\/doi.org\/10.1016\/j.hfc.2014.04.008.","journal-title":"Heart Fail Clin"},{"key":"2408_CR33","doi-asserted-by":"publisher","first-page":"9706","DOI":"10.3748\/wjg.v22.i44.9706","volume":"22","author":"N Pejnovic","year":"2016","unstructured":"Pejnovic N, Jeftic I, Jovicic N, Arsenijevic N, Lukic ML. Galectin-3 and IL-33\/ST2 axis roles and interplay in diet-induced steatohepatitis. World J Gastroenterol. 2016;22:9706\u201317. https:\/\/doi.org\/10.3748\/wjg.v22.i44.9706.","journal-title":"World J Gastroenterol"},{"key":"2408_CR34","doi-asserted-by":"publisher","unstructured":"Wettersten N, Maisel AS, Miller A, McNamara J, Hummel SL, Konerman MC. Biomarkers for heart failure: an update for practitioners of internal medicine. Am J Med, TincopaMA. Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction. Sci Rep 2020;10:12440. https:\/\/doi.org\/10.1016\/j.amjmed.2016.01.013","DOI":"10.1016\/j.amjmed.2016.01.013"},{"key":"2408_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ehf2.12222","volume":"5","author":"A Yoshihisa","year":"2018","unstructured":"Yoshihisa A, Sato Y, Yokokawa T, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Nakazato K, Saitoh SI, Takeishi Y. Liver brosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail. 2018;5:262\u201370. https:\/\/doi.org\/10.1002\/ehf2.12222.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"2408_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02607-w","volume":"24","author":"D Hullon","year":"2025","unstructured":"Hullon D, Subeh GK, Volkova Y, Janiec K, Trach A, Mnevets R. The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF). Cardiovasc Diabetol. 2025;2470. https:\/\/doi.org\/10.1186\/s12933-025-02607-w.","journal-title":"Cardiovasc Diabetol"},{"key":"2408_CR37","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12933-025-02707-7","volume":"24","author":"Y Lingyun Luo","year":"2025","unstructured":"Lingyun Luo Y, Zuo, Dai L. Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF. Cardiovasc Diabetol. 2025;24:155. https:\/\/doi.org\/10.1186\/s12933-025-02707-7.","journal-title":"Cardiovasc Diabetol"},{"key":"2408_CR38","doi-asserted-by":"publisher","first-page":"100983","DOI":"10.1016\/j.ajpc.2025.100983","volume":"22","author":"M Rachel","year":"2025","unstructured":"Rachel M, Bond K, Crumbs IvyTre\u2019Cherie, Purewal V, Obang S, Dan Inder S, Sraow. Coronary microvascular dysfunction and its role in heart failure withpreserved ejection fraction for future prevention and treatment. Am J Prev Cardiol. 2025;22:100983. https:\/\/doi.org\/10.1016\/j.ajpc.2025.100983.","journal-title":"Am J Prev Cardiol"},{"key":"2408_CR39","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1161\/CIRCULATIONAHA.109.912774","volume":"121","author":"B Lopez","year":"2010","unstructured":"Lopez B, Gonzalez A, Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 2010;121:1645\u201354. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.912774.","journal-title":"Circulation"},{"key":"2408_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cca.2014.06.028","volume":"443","author":"GK Chalikias","year":"2015","unstructured":"Chalikias GK, Tziakas DN. Biomarkers of the extracellular matrix and of collagen fragments. Clin Chim Acta. 2015;443:39\u201347. https:\/\/doi.org\/10.1016\/j.cca.2014.06.028.","journal-title":"Clin Chim Acta"},{"key":"2408_CR41","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ijcard.2017.01.089","volume":"236","author":"K Nagao","year":"2017","unstructured":"Nagao K, Tamura A, Morimoto T, Shimamura K, Yukawa H, Ito H, Hayashi F, Makita T, Takemura G, Sato Y, Inada T, Kimura T, Tanaka M. Liver fibrogenesis marker, 7S domain of colla- gen type IV in patients with acutely de- compensated heart failure: correlates, prognostic value and time course. Int J Cardiol. 2017;236:483\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2017.01.089.","journal-title":"Int J Cardiol"},{"key":"2408_CR42","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ehf2.12222","volume":"5","author":"Y Akiomi Yoshihisa","year":"2018","unstructured":"Akiomi Yoshihisa Y, Sato T, Yokokawa T, Sato S, Suzuki M, Oikawa A, Kobayashi T, Yamaki H, Kunii K, Nakazato. Shu-ichi Saitoh and Yasuchika Takeishi. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail. 2018;5:262\u201370. https:\/\/doi.org\/10.1002\/ehf2.12222.","journal-title":"ESC Heart Fail"},{"issue":"5","key":"2408_CR43","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkerdy GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA, SUMMIT Trial Study Group. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"issue":"21","key":"2408_CR44","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V, ESSENCE Study Group. Phase 3 Trial of Semaglutide in Metabolic Dysfunction\u2013Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med"},{"issue":"6","key":"2408_CR45","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","volume":"79","author":"PN Newsome","year":"2023","unstructured":"Newsome PN, Ambery P. Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver. J Hepatol. 2023;79(6):1557\u201365. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.033.","journal-title":"J Hepatol"}],"updated-by":[{"DOI":"10.1007\/s11886-026-02422-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000}}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02408-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02408-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02408-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:03:33Z","timestamp":1790276613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02408-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2408"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02408-x","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The corresponding author\u2019s name was incorrectly written as \u201cMona A. Hegzay\u201d. The correct name is \u201cMona A. Hegazy\u201d.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11886-026-02422-z","URL":"https:\/\/doi.org\/10.1007\/s11886-026-02422-z","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"<b>Consent for Publications<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"92"}}